Voicebrook and Gestalt Debuting Strategic Integration at Pathology Visions 2022
Now Available - VoiceOver PRO and PathFlow® integration to improve streamlined workflow for laboratories
October 16, 2022
–Lake Success, NY, and Spokane, WA. Gestalt Diagnostics and Voicebrook will be debuting and demonstrating our strategic integration to benefit real-time data integration in the pathologist’s workflow. The tight integration of Voicebrook’s VoiceOver PRO software directly within Gestalt’s digital pathology workflow solution, PathFlow, will positively impact lab efficiency and accuracy through true interoperability.
VoiceOver PRO is the leading speech recognition-based reporting solution tailored to the unique needs of pathology, allowing users to effortlessly create high-quality, standardized reports. PathFlow is the leading digital pathology workflow solution enabling a robust, streamlined and fully integrated workflow for pathologists. The partnership between the two companies will provide a clean, automated experience which supports the unique reporting needs, including synoptic report templates, directly within the digital workflow.
Schedule a demo with us at Booth #400 during your visit to Pathology Visions 22 to learn more.
“Voicebrook looks forward to demonstrating our integration with Gestalt at Pathology Visions 2022,” says E. Bruce Sopko, Vice President of Sales at Voicebrook. “We’ve worked together to streamline the reporting process and provide for seamless interplay with all laboratory systems. Through this partnership with Gestalt, we leverage PRO’s integrated system capabilities to truly ease the compatibility between PathFlow and adjacent pathology technologies in the lab.”
“We are excited to debut this integrated workflow, leveraging the inherent features and functionality that make the strategic relationship between our companies a natural yet progressive step,” says Gestalt COO & Chief Strategy Officer, Lisa-Jean Clifford. “The development and product teams at both of our companies have worked together in a way that embodies our combined values and philosophy of supporting pathologists and pathology labs through innovative technology. Our goal is to support the entire pathologist's workflow through true interoperability so that pathologists can focus on what matters most, their patients.”
With a personal demonstration of this sophisticated integration, you can see first-hand the ability to streamline the reporting process and the seamless integration within PathFlow. With more and more institutions adopting digital pathology, there is a large amount of data and information to manage for each case. All technology solutions in the pathology lab must be able to communicate and share information more readily in order for the full benefits of digital pathology to be recognized.
About Gestalt Diagnostics
Gestalt transforms pathology through an intelligent, configurable, and vendor-neutral digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow® solution is a cloud-based digital pathology enterprise platform that can easily be customized based on your specific preferences.
About Voicebrook
Founded in 2002, Voicebrook is the leading provider of reporting solutions for pathology, with approximately 500 client sites and more than 3600 unique users across the US, Canada, and Australia. The VoiceOver PRO software application incorporates speech recognition, digital dictation, customizable templates, and an assortment of input devices, providing direct integration with the user’s Anatomic Pathology (AP) system. VoiceOver PRO allows pathology professionals to rapidly and accurately create pathology reports, choosing one of three customizable workflows. Learn more at www.voicebrook.com. Follow @voicebrook on Twitter.
Visit our Press Release on the Wire
By Maarion Napora At Gestalt, we understand the role of education for physicians and why it is important to have a focus specifically on pathology. It is our goal to provide the proper digital tools and platforms for pathologists to learn how to use the latest technology in their training. PathFlow ’ s Education Module provides academic medical centers and residency programs with leading tools and digital technology to train the next generation of pathologists. Designed to meet the demands of modern techniques, the module offers the ability to develop courses, easily clone and copy courses, and assign teaching lists, images, and tests. You can set the timing for a course, automatically send out messages to remind students of outstanding courses and test deadlines, etc. We support multiple forms of media, including videos, PowerPoint presentations, and word documents. These enable educators to deliver immersive, digital-first learning experiences. The PathFlow Education Module Revolutionizes pathology training by providing a unified platform for interactive learning. Trainees can access a comprehensive library of annotated digital slides, practice diagnosing complex cases, and receive real-time feedback. Professors can easily grade, provide comments and feedback on assessments, and can even assign certificates. The module’s credentialing management capabilities streamline competency assessments, notifications for deadlines, and reminders if not completed, ensuring residents meet rigorous standards while tracking progress seamlessly. We believe education and access to leading technology is the cornerstone of advancing pathology. With PathFlow’s Education Module, we’re empowering academic programs to train confident, tech-savvy pathologists, who will lead the field forward with current skills in available technology informatics.
Spokane, Washington, July 9, 2025 – Gestalt, a leading provider of AI-powered digital pathology solutions, showcased its AI-powered pathology platform, PathFlow, at the Spring 2025 DICOM WG-26 Interoperability Connectathon, confirming its readiness for real-world clinical integration and multi-vendor environments. The Connectathon was co-sponsored by the Digital Pathology Association (DPA) and the European Society of Digital and Integrative Pathology (ESDIP). The event, hosted virtually from January to June and featured at the European Congress on Digital Pathology in Barcelona, brought together over 30 organizations to validate end-to-end workflows, in varying categories, using DICOM standards. The categories included image acquisition, storage, viewing, and AI-driven annotations. Gestalt’s platform stood out as a leader in interoperability, particularly as an Image Display (Viewer). Gestalt’s Viewer successfully displayed images from 8 of 9 different WSI Scanners, demonstrating seamless compatibility with multiple diverse systems such as 3DHISTECH, Grundium, Leica, Hamamatsu and Pramana. This robust performance ensures pathologists can access high-quality whole slide images effortlessly, regardless of the source, streamlining diagnostic workflows. Additionally, PathFlow excelled in displaying annotations from five AI Evidence Creators, including industry leaders like Visiopharm, Hologic, TechCyte and identify.bio, further demonstrating its ability to present structured data for precise diagnostic insights. As an Evidence Creator itself, (AI Annotations), Gestalt showcased its advanced AI capabilities, by analyzing and annotating images from eight scanners. These annotations were successfully transmitted to five different image management archives using standard DICOM Web protocols, highlighting Gestalt’s ability to deliver accurate, standards-compliant AI-driven outputs. This functionality empowers pathologists to integrate AI seamlessly into routine clinical operations, improving efficiency and diagnostic accuracy. “Gestalt’s performance at the Connectathon reflects our dedication to building interoperable, scalable solutions that empower pathologists globally,” said Brian Napora, VP of Innovation, Gestalt Diagnostics. “By investing in open standards, we’re helping lead digital pathology toward a more integrated and intelligent future.” The Connectathon’s rigorous testing environment validated Gestalt’s ability to handle real-world challenges, such as legacy image integration and complex multi-vendor workflows without requiring custom workarounds. Gestalt’s commitment to DICOM standards positions PathFlow as a cornerstone for vendor-neutral, future-ready pathology solutions. About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn
July 2025 Digipath Dispatch – Industry news, digital pathology insights, product updates, and events from Gestalt Diagnostics.
Gestalt’s PathFlow and PathCloud unify pathology workflows, enabling seamless, multi-vendor integration for faster, accurate diagnoses.
Discover why digital pathology is gaining momentum and how it’s shaping diagnostics, improving workflows, and addressing workforce challenges in healthcare.
Discover how Lisa-Jean Clifford is helping shape the future of AI in pathology through a new framework designed for safe, scalable clinical integration.
Spokane, Washington, June 17, 2025 – Gestalt, a leading provider of AI-powered digital pathology solutions, today announced the addition of Dr. Renuka Kulkarni, MD, as Chief Medical Officer (CMO). A physician scientist with over 20 years of experience in surgical and digital pathology, Dr. Kulkarni will join the team in guiding Gestalt’s product direction and clinical usability. Dr. Kulkarni brings a rare blend of diagnostic precision and scientific innovation to the organization. Her expertise in breast pathology, immunomarkers, machine learning, and image analysis strengthens Gestalt’s mission to revolutionize diagnostic workflows and clinical decision-making through technology. “Renuka’s addition signals our deepening investment in the future of pathology,” said Lisa-Jean Clifford, President of Gestalt Diagnostics. “Her leadership and experience at the intersection of clinical insight, AI, and enterprise lab operations will ensure our solutions continue to serve both pathologists and the patients they care for.” Before joining Gestalt, Dr. Kulkarni played a pivotal role in developing one of the earliest digital pathology programs at a leading full-service reference laboratory. Her extensive hands-on experience with Gestalt’s solutions, as a customer and direct user for four years, along with image analysis platforms, and combined with her understanding of real-world lab operations, positions her to help bridge the clinical and commercial realms—ensuring the scalability and impact of Gestalt’s solutions. As CMO, Dr. Kulkarni will help shape the development of next-generation diagnostic tools, supporting Gestalt’s mission to enhance diagnostic accuracy, efficiency, and interoperability across health systems worldwide. “I’m honored to join Gestalt at such a transformative moment in digital pathology,” said Dr. Kulkarni. “Together, we have the opportunity to shape solutions that truly serve pathologists and ultimately improve outcomes for patients everywhere.” About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn
Date : Wednesday, May 21, 2025 Time : 1:45 PM Location : Auditorium 1, Marriott Eagle Crest Resort (Ann Arbor, Michigan) Session Title : The Long-Term Advantages of Digital Pathology are Only Realized Through True Interoperability We’re proud to announce that Lisa-Jean Clifford , COO & Chief Strategy Officer at Gestalt Diagnostics, and Sumie Edwards (ARUP) will take the stage at the 2025 Pathology Informatics Summit to share key insights into the critical role of interoperability in digital pathology. In this featured session, Lisa-Jean will explore: Why interoperability is the linchpin for scalable, future-ready digital pathology programs How health systems can unlock long-term value and efficiency through seamless integration Real-world considerations for IT infrastructure, workflow design, and cross-platform compatibility Her session will offer a strategic lens into how institutions can achieve meaningful digital transformation, not just implement new tools. About the PI Summit : The Pathology Informatics Summit is a premier annual event for professionals at the forefront of digital pathology, laboratory medicine, AI, and healthcare data innovation. It brings together leading physicians, researchers, and informaticists to discuss the rapidly evolving field. Mark your calendar for May 21 at 1:45 PM to hear Lisa-Jean share her vision for a more connected and impactful future in pathology.
Date : Thursday, May 22, 2025 Time : 9:00 AM – 12:00 PM Location : Auditorium 1, Marriott Eagle Crest Resort (Ann Arbor, Michigan) Panel Title : API Focus Session: Expert Panel on LDT Regulation Overhaul and Data Challenges in Pathology Informatics Join Lisa-Jean Clifford , COO & Chief Strategy Officer at Gestalt Diagnostics, for an important panel discussion at the 2025 Pathology Informatics Summit alongside top voices in the field of pathology informatics. This focus session will dive into: The impact of the FDA’s Final Rule on Laboratory Developed Tests (LDTs) Data governance, standardization, and access challenges for AI in pathology The urgent need for broadly sourced datasets to support the next generation of clinical AI models Panel Moderator : Ulysses Balis, MD Expert Panelists : Victor Brodsky, MD – Washington University School of Medicine, St. Louis Lisa-Jean Clifford – Gestalt Diagnostics Bruce Friedman, MD Ronald Jackups, MD, PhD – Washington University School of Medicine, St. Louis Amrom Obstfeld, MD, PhD – Children’s Hospital of Philadelphia Michelle Stoffel, MD, PhD – University of Minnesota J. Mark Tuthill, MD – Henry Ford Health System This dynamic session includes two panel discussions followed by open Q&A: The FDA’s Final Rule on LDTs The Growing Crisis of Limited AI Training Data in Pathology Why it matters : With regulatory landscapes shifting and AI innovation surging, this session offers a rare chance to hear from experts shaping the future of diagnostics, data ethics, and clinical technology adoption. Don’t miss this opportunity to learn from Lisa-Jean and fellow leaders who are building the next chapter of pathology informatics.
Spokane, Washington, April 28, 2025 – Gestalt, a leading innovator in AI-powered digital pathology solutions, announced the completion of a $7.5 million Series A financing. The round was led by Cowles Ventures, TVF Funds, Inland Imaging Investments, KickStart Funds, and prominent angel investors from the Pacific Northwest. Gestalt’s PathFlow® platform is used by leading healthcare, academic medical centers, and research organizations. Customers implement PathFlow as their preferred solution because it integrates seamlessly into their existing laboratory information systems, enabling faster, more accurate diagnoses and improving access to expert consultation, education, and research—regardless of location. "PathFlow is transforming pathology by leveraging robust digital workflows and AI algorithms to support scoring of key biomarkers. This enables organizations to accurately match patients to known therapies and generate rich datasets for research and new drug development," said Dan Roark, CEO, Gestalt. "Our technology is designed to improve patient outcomes by enabling faster, more accurate diagnoses and broadening access to clinical expertise." This new funding will facilitate broader market adoption and increased profitability. The capital will be used to expand the company’s customer base, enhance AI capabilities, and pursue FDA clearance. This comes at a critical moment, with rising cancer rates and a declining number of practicing pathologists intensifying the need for scalable, digital-first diagnostic solutions. “We are incredibly grateful for the continued support from our investors,” Roark added. “This funding allows us to expand on the solid foundation we’ve built. We’ve already streamlined how pathologists navigate fragmented systems by creating PathFlow, a unified platform for viewing pathology cases digitally and collaborating with leading experts in real-time without the need to ship specimens. Now, we’ll accelerate innovation and scale our reach to meet the growing demands of modern pathology.” Gestalt is at the forefront of a critical shift in diagnostic medicine, helping transform pathology from a manual, microscope-based process to a scalable digital solution leveraging artificial intelligence tools — like the digital transitions already seen in radiology and cardiology. The company’s platform not only improves diagnostic speed and precision which is critical for cancer patients who can wait for days to weeks or more for a diagnosis, but also unlocks AI-powered insights that enable: Biomarker scoring to support the optimization of patient-therapy matching, Image and data analysis for disease progression studies, And the interoperability that enables pathologists access to valuable aides and insights that streamline their workflows, highlight areas of positivity and reduce missed diagnoses. With this Series A funding, Gestalt remains committed to expanding its impact through the deployment of its’ PathFlow software in healthcare, making high-quality, scalable pathology solutions more accessible to clinicians and researchers worldwide. About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn
